Rallybio Stock Drops: 2025 Study Plans Announced
Wednesday, Jun 4, 2025 7:18 pm ET1min read
RLYB--
Rallybio Corporation plunged 2.39% in after-hours trading, following the company's announcement of plans to initiate confirmatory pharmacokinetics and pharmacodynamics studies for RLYB116 in the second quarter of 2025, with data expected to be released in the third and fourth quarters of the same year. The company's stock had previously surged 35.87% to $0.40 during Wednesday's trading, reaching a market capitalization of $16.6 million.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet